

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-62 (canceled).

Claim 63 (currently amended). An agent[[,]] for the treatment of pain, ~~that~~ which comprises:~~[[,]]~~ a galactose-binding or an N-acetylgalactosamine-binding lectin; a light (L) chain or an L-chain fragment of a clostridial neurotoxin, which L-chain or L-chain fragment ~~includes~~ contains the proteolytically active ~~proteolytic~~ enzyme domain of the L-chain; and ~~[[a]]~~ the translocation domain of a clostridial neurotoxin H-chain; wherein the ~~galactose-binding-lectin,~~ L-chain or L-chain fragment[[,]] and the translocation domain of ~~[[a]]~~ the clostridial neurotoxin H-chain are linked ~~together~~ by a ~~covalent~~ disulfide bond to form LH_N, and wherein the LH_N and the lectin are linked together by contacting the LH_N and the lectin with one or more chemical coupling agents; and wherein:

- ~~(a) — the lectin is of bacterial origin; or~~
- ~~(b) — the lectin has been contacted with a modifying chemical, and retains an ability to bind to an oligosaccharide structure having an exposed galactose or N-acetylgalactosamine residue.~~

Claim 64 (canceled).

Claim 65 (previously presented). The agent according to Claim 63, wherein the lectin is of bacterial origin.

Claim 66 (previously presented). The agent according to Claim 65, wherein the lectin is obtained from *Pseudomonas aeruginosa*.

Claim 67-70 (canceled).

Claim 71. (new) The agent according to claim 63, wherein the LH_N and the lectin are linked by SPD_P.